JPWO2020059772A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020059772A5 JPWO2020059772A5 JP2020548575A JP2020548575A JPWO2020059772A5 JP WO2020059772 A5 JPWO2020059772 A5 JP WO2020059772A5 JP 2020548575 A JP2020548575 A JP 2020548575A JP 2020548575 A JP2020548575 A JP 2020548575A JP WO2020059772 A5 JPWO2020059772 A5 JP WO2020059772A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- her3
- therapeutic agent
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024086183A JP2024109885A (ja) | 2018-09-20 | 2024-05-28 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018175510 | 2018-09-20 | ||
| JP2018175510 | 2018-09-20 | ||
| PCT/JP2019/036668 WO2020059772A1 (ja) | 2018-09-20 | 2019-09-19 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086183A Division JP2024109885A (ja) | 2018-09-20 | 2024-05-28 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2020059772A1 JPWO2020059772A1 (ja) | 2021-08-30 |
| JPWO2020059772A5 true JPWO2020059772A5 (https=) | 2022-09-16 |
Family
ID=69887630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548575A Pending JPWO2020059772A1 (ja) | 2018-09-20 | 2019-09-19 | 抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
| JP2024086183A Pending JP2024109885A (ja) | 2018-09-20 | 2024-05-28 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086183A Pending JP2024109885A (ja) | 2018-09-20 | 2024-05-28 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12527979B2 (https=) |
| EP (1) | EP3854418A4 (https=) |
| JP (2) | JPWO2020059772A1 (https=) |
| KR (1) | KR20210062005A (https=) |
| CN (1) | CN112912109A (https=) |
| BR (1) | BR112021005246A2 (https=) |
| WO (1) | WO2020059772A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186295A1 (en) * | 2020-06-08 | 2021-12-16 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
| CN116133694B (zh) * | 2020-10-14 | 2026-03-06 | 苏州盛迪亚生物医药有限公司 | 抗her3抗体和抗her3抗体药物偶联物及其医药用途 |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药（苏州）股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| CN117677400A (zh) * | 2021-09-16 | 2024-03-08 | 正大天晴药业集团股份有限公司 | 抗her3抗体药物偶联物及其组合物和用途 |
| AU2023213783A1 (en) * | 2022-01-28 | 2024-08-15 | Duality Biologics (Suzhou) Co., Ltd. | Her3 antibody-drug conjugate and use thereof |
| EP4514396A1 (en) * | 2022-04-29 | 2025-03-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugates and preparation methods and use thereof |
| PE20252676A1 (es) * | 2023-01-03 | 2025-11-24 | Hummingbird Bioscience Pte Ltd | Conjugado anticuerpo-farmaco que se une a her3 |
| EP4727593A1 (en) * | 2023-06-15 | 2026-04-22 | Fortvita Biologics (Singapore) Pte. Ltd. | Formulation comprising antibody-drug conjugate targeting claudin18.2, method for preparing the same, and use thereof |
| CN121752297A (zh) * | 2023-09-01 | 2026-03-27 | 四川科伦博泰生物医药股份有限公司 | 抗体-药物缀合物及其制备方法和用途 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025108438A1 (zh) * | 2023-11-24 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法 |
| WO2025248072A1 (en) * | 2024-05-30 | 2025-12-04 | BioNTech SE | Use of anti-her3 antibody-drug conjugates in cancer treatment |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US6774116B2 (en) | 2001-04-17 | 2004-08-10 | Cryolife, Inc. | Prodrugs via acylation with cinnamate |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| WO2006135371A1 (en) | 2005-06-09 | 2006-12-21 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| EP2069308B1 (en) | 2006-09-12 | 2017-03-29 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Azonafide derived tumor and cancer targeting compounds |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| EP3912643B8 (en) | 2009-02-13 | 2023-08-23 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| CN104447995A (zh) | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| CA2777242A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| CN102884085B (zh) | 2010-04-09 | 2016-08-03 | Aveo制药公司 | 抗erbb3抗体 |
| MX391454B (es) | 2010-04-15 | 2025-03-05 | Seagen Inc | Compuesto de engarce-fármaco para conjugación a una unidad de ligando. |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| WO2012064733A2 (en) | 2010-11-09 | 2012-05-18 | Medimmune, Llc | Antibody scaffold for homogenous conjugation |
| HK1200468A1 (en) | 2011-09-30 | 2015-08-07 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| RU2014126098A (ru) * | 2011-11-30 | 2016-01-27 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
| CA2862925C (en) | 2012-02-10 | 2020-01-21 | University Of Maryland, Baltimore | Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| US9725511B2 (en) * | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4 |
| JP6262768B2 (ja) | 2013-01-03 | 2018-01-17 | セルトリオン， インク． | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| WO2014134457A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| KR102399277B1 (ko) * | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| MX2016014416A (es) * | 2014-05-14 | 2017-02-23 | Hoffmann La Roche | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. |
| WO2016172584A1 (en) * | 2015-04-24 | 2016-10-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies |
| TW202523682A (zh) * | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| US10516432B2 (en) * | 2016-12-01 | 2019-12-24 | Mediatek Inc. | Communication system with switchable devices |
| KR20240074000A (ko) * | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| ES3057444T3 (en) | 2017-08-31 | 2026-03-02 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
-
2019
- 2019-09-19 KR KR1020217007188A patent/KR20210062005A/ko not_active Ceased
- 2019-09-19 EP EP19863647.4A patent/EP3854418A4/en active Pending
- 2019-09-19 BR BR112021005246-1A patent/BR112021005246A2/pt unknown
- 2019-09-19 WO PCT/JP2019/036668 patent/WO2020059772A1/ja not_active Ceased
- 2019-09-19 JP JP2020548575A patent/JPWO2020059772A1/ja active Pending
- 2019-09-19 US US17/276,394 patent/US12527979B2/en active Active
- 2019-09-19 CN CN201980061665.4A patent/CN112912109A/zh active Pending
-
2024
- 2024-05-28 JP JP2024086183A patent/JP2024109885A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020059772A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2025041725A5 (https=) | ||
| ES2772348T3 (es) | Dímeros de Nanobody con uniones cisteína | |
| JP2018504105A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| AU2021290305A1 (en) | Nanobody dimers linked via C-terminally engineered cysteins | |
| JPWO2020031936A5 (https=) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2011505146A5 (https=) | ||
| FI3283521T3 (fi) | Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan | |
| FI4212552T3 (fi) | Anti-her2-vasta-aine-lääkeainekonjugaatti | |
| HRP20210593T1 (hr) | Anti-her3 antitijelo-lijek konjugat | |
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2012500814A5 (https=) | ||
| FI3722310T3 (fi) | Vegf:ää estäviä stabiileja ja liukoisia vasta-aineita | |
| JP2013166763A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| HRP20130903T1 (hr) | Heparin-vezujuä†i epidermalnom äśimbeniku rasta sliäśni vezujuä†i proteini antigena äśimbenika rasta | |
| JP2014088414A5 (https=) | ||
| JP2010163438A5 (https=) | ||
| JPWO2020027100A5 (https=) | ||
| JP2016528251A5 (https=) |